Table 1 Clinical characteristics of the patients in the training and test cohorts
Characteristics | Training Cohort (n = 322) | Test Cohort (n = 79) | ||||
|---|---|---|---|---|---|---|
LNM negative | LNM positive | p value | LNM negative | LNM positive | p value | |
n = 184 | n = 138 | n = 44 | n = 35 | |||
RadsScore, mean (SD) | 0.23 (0.21) | 0.69 (0.27) | <0.05 | 0.34 (0.29) | 0.74 (0.23) | <0.05 |
Age, mean (SD) | 54.7 (8.40) | 53.3 (9.09) | 0.163 | 56.8 (7.93) | 55.6 (9.34) | 0.556 |
Menopausal status, n (%) | 0.391 | 1 | ||||
No | 61 (33.2%) | 53 (38.4%) | 13 (29.5%) | 11 (31.4%) | ||
Yes | 123 (66.8%) | 85 (61.6%) | 31 (70.5%) | 24 (68.6%) | ||
US-reported pelvic fluid, n (%) | 2.16 (2.41) | 3.91 (3.23) | <0.05 | 2.01 (1.92) | 2.84 (2.87) | 0.147 |
Lateral | <0.05 | 0.116 | ||||
Unilateral | 112 (60.9%) | 63 (45.7%) | 29 (65.9%) | 16 (45.7%) | ||
Bilateral | 72 (39.1%) | 75 (54.3%) | 15 (34.1%) | 19 (54.3%) | ||
US-reported peritoneal thickening, n (%) | <0.05 | <0.05 | ||||
No | 163 (88.6%) | 78 (56.5%) | 38 (86.4%) | 18 (51.4%) | ||
Yes | 21 (11.4%) | 60 (43.5%) | 6 (13.6%) | 17 (48.6%) | ||
US-reported pelvic wall nodules, n (%) | <0.05 | 0.102 | ||||
No | 163 (88.6%) | 95 (68.8%) | 37 (84.1%) | 23 (65.7%) | ||
Yes | 21 (11.4%) | 43 (31.2%) | 7 (15.9%) | 12 (34.3%) | ||
Maximum diameter, mean (SD) | 9.50 (4.18) | 9.55 (4.03) | 0.912 | 9.15 (3.36) | 9.24 (3.73) | 0.91 |
CA125, median (IQR) | 254 [77.9;564] | 840 [398;1709] | <0.05 | 302 [74.6;613] | 530 [139;1097] | <0.05 |
HE4, median (IQR) | 191 [105;363] | 448 [243;710] | <0.05 | 152 [102;229] | 251 [152;518] | <0.05 |
CEA, median (IQR) | 1.52 [0.94;2.08] | 1.17 [0.78;1.98] | <0.05 | 1.39 [0.88;2.13] | 1.52 [0.96;2.14] | 0.487 |
CA724, median (IQR) | 6.91 [2.83;20.8] | 19.6 [7.15;64.2] | <0.05 | 7.95 [4.26;13.7] | 10.7 [6.28;21.5] | 0.186 |